Tag Archives: 09-16576

Oscient Pharmaceuticals Corporation (f/k/a Genome Therapeutics Corp.) Bankruptcy New Filing Alert: Order Regarding The Motion/Application For Approval Of A Settlement Pursuant To Rule 9019





On April 8, 2014, an order regarding the motion/application for approval of a settlement pursuant to rule 9019 was filed in the bankruptcy case of Oscient Pharmaceuticals Corporation (f/k/a Genome Therapeutics Corp.) and its affiliates. The filing was assigned docket number 1135 and is described on the court’s official docket as follows:

Order Dated 4/8/14 Granting [1134] Motion filed by Trustee Stephen B. Darr, Trustee of the Oscient Trust to Approve Settlement Re: [1101] Complaint. See Order for Full Text. (cl)

Oscient Pharmaceuticals Corporation (f/k/a Genome Therapeutics Corp.) filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on July 13, 2009. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Massachusetts. The case number for the lead bankruptcy case is 09-16576. The bankruptcy case is currently assigned to United States Bankruptcy Judge Henry Boroff. The law firm of Unknown is acting as lead bankruptcy counsel to Oscient Pharmaceuticals Corporation (f/k/a Genome Therapeutics Corp.) in the bankruptcy case.

* * * * * * * * * * * * * * * * * * * *

Chapter 11 Dockets is the most efficient, effective way to research bankruptcy cases and identify precedent.

Because it was designed by experienced restructuring professionals and is chapter 11 specific in focus, Chapter 11 Dockets is optimized for the unique needs of bankruptcy practitioners.

Learn more and sign up for a free trial by visiting http://info.chapter11dockets.com/about-chapter-11-dockets

* * * * * * * * * * * * * * * * * * * *